RA Session II
2020
In 2020, RA Session II earned a total compensation of $4.7M as President, Chief Executive Officer and Director at Taysha Gene Therapies.
Compensation breakdown
| Non-Equity Incentive Plan | $271,878 |
|---|---|
| Salary | $362,594 |
| Stock Awards | $4,060,626 |
| Other | $154 |
| Total | $4,695,252 |
Session received $4.1M in stock awards, accounting for 86% of the total pay in 2020.
Session also received $271.9K in non-equity incentive plan, $362.6K in salary and $154 in other compensation.
Rankings
In 2020, RA Session II's compensation ranked 2,370th out of 13,090 executives tracked by ExecPay. In other words, Session earned more than 81.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,370 out of 13,090 | 82nd |
Division Manufacturing | 908 out of 5,621 | 84th |
Major group Chemicals And Allied Products | 323 out of 2,254 | 86th |
Industry group Drugs | 274 out of 1,954 | 86th |
Industry Biological Products, Except Diagnostic Substances | 77 out of 411 | 81st |
Source: SEC filing on April 28, 2022.
Session's colleagues
We found two more compensation records of executives who worked with RA Session II at Taysha Gene Therapies in 2020.